Employees: 4,963
Size Earth (4985.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $687M, the 921st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,930 on 18 Nov 2026.
Performance Over six months the shares gained 6.9%, against -10.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 4.4% over the last twelve months (peer median +4.3%); the operating margin is 3.6% (peer median 12.4%).
Valuation It trades at 18.0× forward earnings against a peer median of 14.9× (5th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥185B | ¥179B | ¥169B | ¥158B | ¥152B |
| Revenue growth | — | +6% | +7% | +4% | — |
| Gross profit | ¥73.5B | ¥72.6B | ¥66.8B | ¥61.8B | ¥60.6B |
| EBITDA | ¥11.7B | ¥12.8B | ¥11.0B | ¥10.6B | ¥11.7B |
| Net income | ¥3.78B | ¥5.24B | ¥3.48B | ¥4.10B | ¥5.30B |
| Free cash flow | n/a | ¥7.85B | ¥10.1B | ¥3.08B | -¥992M |
| Capital expenditure | n/a | ¥4.17B | ¥4.77B | ¥6.04B | ¥5.89B |
| Total debt | ¥1.61B | ¥7.92B | ¥5.24B | ¥10.2B | ¥2.40B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4985.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | -4.3% | 7th highest of 21 |
| 6-month return | +6.9% | -10.1% | 4th highest of 21 |
| Distance from 52-week high | -6.1% | -32.9% | highest of 21 |
| Revenue growth (TTM) | +4.4% | +4.3% | 9th highest of 18 |
| Operating margin | 3.6% | 12.4% | 6th lowest of 18 |
| Forward P/E | 18.0× | 14.9× | 5th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | -1.6% | 5.9% | 4th least demanding of 10 |
| Growth delivered (Del g) | -1.8% | +6.4% | 2nd lowest of 10 |
| Hurdle (Req g minus delivered) | +0.2 pp | -4.3 pp | 4th most demanding of 10 |
| ROIC minus cost of capital | +1.2 pp | +0.0 pp | 6th highest of 16 |
| EV / EBITDA | 8.4× | 3.8× | 3rd most expensive of 8 |
| Net debt / EBITDA | -1.5× | -1.2× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | n/a | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | n/a | 25.2% | +10.3% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 32.2× | 27.1% | +31.4% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |